Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CILGAVIMAB\TIXAGEVIMAB Cause Breakthrough covid-19? 51 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 51 reports of Breakthrough covid-19 have been filed in association with CILGAVIMAB\TIXAGEVIMAB. This represents 2.4% of all adverse event reports for CILGAVIMAB\TIXAGEVIMAB.

51
Reports of Breakthrough covid-19 with CILGAVIMAB\TIXAGEVIMAB
2.4%
of all CILGAVIMAB\TIXAGEVIMAB reports
6
Deaths
34
Hospitalizations

How Dangerous Is Breakthrough covid-19 From CILGAVIMAB\TIXAGEVIMAB?

Of the 51 reports, 6 (11.8%) resulted in death, 34 (66.7%) required hospitalization, and 1 (2.0%) were considered life-threatening.

Is Breakthrough covid-19 Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CILGAVIMAB\TIXAGEVIMAB. However, 51 reports have been filed with the FAERS database.

What Other Side Effects Does CILGAVIMAB\TIXAGEVIMAB Cause?

Covid-19 (521) Drug ineffective (123) Product use issue (94) Fatigue (86) Headache (86) Dyspnoea (84) Pyrexia (81) Nausea (68) Dizziness (64) Pneumonia (49)

What Other Drugs Cause Breakthrough covid-19?

RITUXIMAB (84) PREDNISONE (44) CYCLOPHOSPHAMIDE (30) VINCRISTINE (29) DOXORUBICIN (26) METHOTREXATE (26) BENDAMUSTINE (23) TOZINAMERAN (19) ELASOMERAN (18) MYCOPHENOLATE MOFETIL (18)

Which CILGAVIMAB\TIXAGEVIMAB Alternatives Have Lower Breakthrough covid-19 Risk?

CILGAVIMAB\TIXAGEVIMAB vs CILOSTAZOL CILGAVIMAB\TIXAGEVIMAB vs CILTACABTAGENE AUTOLEUCEL CILGAVIMAB\TIXAGEVIMAB vs CIMETIDINE CILGAVIMAB\TIXAGEVIMAB vs CIMZIA CILGAVIMAB\TIXAGEVIMAB vs CINACALCET

Related Pages

CILGAVIMAB\TIXAGEVIMAB Full Profile All Breakthrough covid-19 Reports All Drugs Causing Breakthrough covid-19 CILGAVIMAB\TIXAGEVIMAB Demographics